Orphan Status

race track
Biotech

Ovid's fragile X drug shows promise in phase 2

Ovid Therapeuctics’ lead program improved behavioral symptoms, as well as anxiety and mood, in a small phase 2 study in fragile X syndrome.
Amirah Al Idrus May 7, 2020 10:35am
Lungs

FDA still not happy with Kamada inhaled AAT drug

Apr 23, 2018 9:45am
Wall Street

Barclays loses patience with Gilead, tells it to change up its strategy

Mar 10, 2017 4:16am
Money

Fidelity backs rare disease startup with $48M to get pivotal data

Oct 3, 2016 9:43am